{"protocolSection":{"identificationModule":{"nctId":"NCT03717155","orgStudyIdInfo":{"id":"MS201944_0170"},"secondaryIdInfos":[{"id":"2018-001529-24","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"},"briefTitle":"Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC","officialTitle":"A Phase IIa, Single-arm, Multicenter Study to Investigate the Clinical Activity and Safety of Avelumab in Combination With Cetuximab Plus Gemcitabine and Cisplatin in Participants With Advanced Squamous NSCLC"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-10-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-30","type":"ACTUAL"},"completionDateStruct":{"date":"2021-05-27","type":"ACTUAL"},"studyFirstSubmitDate":"2018-10-22","studyFirstSubmitQcDate":"2018-10-22","studyFirstPostDateStruct":{"date":"2018-10-24","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-09-23","resultsFirstSubmitQcDate":"2021-11-08","resultsFirstPostDateStruct":{"date":"2021-11-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-05-13","lastUpdatePostDateStruct":{"date":"2022-06-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck KGaA, Darmstadt, Germany","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of the study was to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with treatment-naïve advanced squamous non-small-cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Squamous Non-Small Cell Lung Cancer"],"keywords":["Avelumab","Cetuximab","Cisplatin","Gemcitabine","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":43,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Avelumab and Cetuximab","type":"EXPERIMENTAL","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.","interventionNames":["Drug: Avelumab","Drug: Cetuximab","Drug: Gemcitabine","Drug: Cisplatin","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Avelumab","description":"Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.","armGroupLabels":["Avelumab and Cetuximab"]},{"type":"DRUG","name":"Cetuximab","description":"Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\\^2) body surface area on Day 1 and 500 mg/m\\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.","armGroupLabels":["Avelumab and Cetuximab"]},{"type":"DRUG","name":"Gemcitabine","description":"Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.","armGroupLabels":["Avelumab and Cetuximab"]},{"type":"DRUG","name":"Cisplatin","description":"Participants received cisplatin intravenous infusions at a dose of 75 mg/m\\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.","armGroupLabels":["Avelumab and Cetuximab"]},{"type":"DRUG","name":"Carboplatin","description":"In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.","armGroupLabels":["Avelumab and Cetuximab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator","description":"Confirmed BOR was defined as the percentage of participants who achieved confirmed complete responses (CR) or partial response (PR), according to RECIST version 1.1 assessed by the Investigator.CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Stable disease (SD)= Neither sufficient increase to qualify for progression of disease (PD) nor sufficient shrinkage to qualify for PR. PD: At least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Confirmed CR=as at least two determinations of CR at least 4 weeks apart with no PD. Confirmed PR=as at least 2 determinations of PR or better (PR followed by PR or PR followed by CR), at least 4 weeks apart (not qualifying for a CR) with no PD in between. Percentage of Participants with confirmed BOR were reported.","timeFrame":"Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 612 days)"}],"secondaryOutcomes":[{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs)","description":"Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug.Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious and non-serious TEAEs. irAEs included AEs that matches a preferred term on the list of pre-selected MedDRA terms. AEs with relationship to study treatment are reported as Treatment-related AEs. Treatment related AEs with grade 3 or more is also reported.","timeFrame":"Time from the first dose of study drug assessed up to (941 days)"},{"measure":"Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","description":"Progression free survival (PFS) is defined as the time (in months) from first treatment day to the date of the first documentation of objective progression of disease (PD) according to RECIST version 1.1 assessed by Investigator, or death due to any cause, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 737 days)"},{"measure":"Duration of Response (DOR)","description":"DOR is defined for participants with confirmed complete response (CR) or partial response (PR), as the time from first documentation of confirmed response to the date of first documentation of progression of disease (PD) according to RECIST version 1.1 (assessed by Investigator) or death due to any cause or tumor assessment. Duration of objective response was assessed using Kaplan-Meier analysis. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","timeFrame":"Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 612 days)"},{"measure":"Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab","description":"Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed Avelumab concentration-time data.","timeFrame":"Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337"},{"measure":"Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab","description":"Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed cetuximab concentration-time data.","timeFrame":"Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337"},{"measure":"Serum Trough Concentration Levels (Ctrough) of Avelumab","description":"Ctrough is the serum concentration observed immediately before next dosing.","timeFrame":"Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337"},{"measure":"Serum Trough Concentration Levels (Ctrough) of Cetuximab","description":"Ctrough is the serum concentration observed immediately before next dosing.","timeFrame":"Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from the first treatment day to the date of death due to any cause. Overall survival was assessed using Kaplan-Meier analysis.","timeFrame":"Time from the first dose of study drug until occurrence of death due to any cause (assessed up to 941 days)"},{"measure":"Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab","description":"The detection of antibodies to avelumab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of avelumab were reported.","timeFrame":"Pre-dose up to 149 days"},{"measure":"Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab","description":"The detection of antibodies to cetuximab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of cetuximab were reported.","timeFrame":"Pre-dose up to 149 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically-confirmed Stage IV metastatic or recurrent (Stage IV) NSCLC of squamous histology\n* Availability of formalin-fixed paraffin-embedded (FFPE) block containing tumor tissue or a minimum of 15 (preferably 25) unstained tumor slides (cut within 1 week) suitable for Programmed death ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) expression/amplification assessments\n* At least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study entry\n* Adequate hematological, hepatic and renal function\n* Estimated life expectancy of at least 3 months\n* Can give signed informed consent\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants whose tumor disease harbors an activating EGFR mutation or ALK rearrangement. Participants with tumors of unknown EGFR or ALK status will require testing only in never smokers\n* All participants with brain metastases with protocol defined exceptions\n* Previous malignant disease (other than NSCLC) within the last 5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least 2 years prior to study entry and the participant was deemed to have been cured with no additional therapy required or anticipated to be required\n* Active infection requiring systemic therapy\n* Known history of human immunodeficiency virus or known acquired immunodeficiency syndrome\n* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV ribonucleic acid (RNA) if anti-HCV antibody screening test positive)\n* Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent\n* Interstitial parenchymal lung disease\n* Pregnancy or lactation\n* Known alcohol or drug abuse as determined by the Investigator\n* History of uncontrolled intercurrent illness\n* Clinically significant (that is active) cardiovascular disease\n* Known history of inflammatory colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis\n* Any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements\n* Prior/Concomitant Therapy as described in protocol\n* Use of any investigational drug within 28 days before the start of study treatment\n* Other protocol defined exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Responsible","affiliation":"Merck KGaA, Darmstadt, Germany","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Semmelweis Egyetem - Pulmonologiai Klinika","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Debreceni Egyetem - Tudogyogyaszati Klinika","city":"Debrecen","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Petz Aladar Megyei Oktato Korhaz - Pulmonologiai Osztaly","city":"Győr","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Markusovszky Egyetemi Oktatokorhaz","city":"Szombathely","zip":"9700","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"facility":"Tudogyogyintezet Torokbalint - Onkopulmonologiai es Jarobeteg centrum","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Zala Megyei Szent Rafael Korhaz","city":"Zalaegerszeg","zip":"8900","country":"Hungary","geoPoint":{"lat":46.83695,"lon":16.84401}},{"facility":"Clinical Center \"Bezanijska kosa\" - Department of Oncology","city":"Belgrade","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Clinical Center Kragujevac (no dept.)","city":"Belgrade","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Institute for Pulmonary Diseases of Vojvodina","city":"Kamenitz","country":"Serbia","geoPoint":{"lat":45.22334,"lon":19.84263}},{"facility":"Complejo Hospitalario Universitario A Coruña - Servicio de Oncologia","city":"A Coruña","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron - Dept of Oncology","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica","city":"Madrid","zip":"28007","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario 12 de Octubre - Servicio de Oncologia","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Regional Universitario de Malaga","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario Virgen Macarena - Servicio de Oncologia","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica","city":"Valencia","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Clinico Universitario Lozano Blesa - Dept of Oncology","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}}]},"referencesModule":{"references":[{"pmid":"36718142","type":"DERIVED","citation":"Andric Z, Galffy G, Cobo Dols M, Szima B, Stojanovic G, Petrovic M, Felip E, Vicente Baz D, Ponce Aix S, Juan-Vidal O, Szalai Z, Losonczy G, Calles Blanco A, Bernabe R, Garcia Ledo G, Aguilar Hernandez A, Duecker K, Zhou D, Schroeder A, Guezel G, Ciardiello F. Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC. JTO Clin Res Rep. 2023 Jan 2;4(2):100461. doi: 10.1016/j.jtocrr.2022.100461. eCollection 2023 Feb."}],"seeAlsoLinks":[{"label":"Trial Awareness and Transparency website","url":"https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS201944_0170"},{"label":"Medical Information Location Map - Med Info Contacts","url":"https://www.merckgroup.com/en/company/contact-us/medinfo-contact-map.html"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 43 participants were enrolled in this study at different sites in Hungary, Serbia and Spain.","groups":[{"id":"FG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"43"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"43"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"43"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63","spread":"7.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"35"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"43"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by Investigator","description":"Confirmed BOR was defined as the percentage of participants who achieved confirmed complete responses (CR) or partial response (PR), according to RECIST version 1.1 assessed by the Investigator.CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Stable disease (SD)= Neither sufficient increase to qualify for progression of disease (PD) nor sufficient shrinkage to qualify for PR. PD: At least a 20 % increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Confirmed CR=as at least two determinations of CR at least 4 weeks apart with no PD. Confirmed PR=as at least 2 determinations of PR or better (PR followed by PR or PR followed by CR), at least 4 weeks apart (not qualifying for a CR) with no PD in between. Percentage of Participants with confirmed BOR were reported.","populationDescription":"Full analysis set includes all participants who received at least one non-zero dose of any study treatment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 612 days)","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","lowerLimit":"21.0","upperLimit":"50.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events (AEs), Treatment-Related Grade >=3 TEAEs and Immune-related Treatment Emergent AEs (irTEAEs)","description":"Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug.Serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious and non-serious TEAEs. irAEs included AEs that matches a preferred term on the list of pre-selected MedDRA terms. AEs with relationship to study treatment are reported as Treatment-related AEs. Treatment related AEs with grade 3 or more is also reported.","populationDescription":"Safety analysis set included all participants who received at least one non-zero dose of any study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Time from the first dose of study drug assessed up to (941 days)","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}]},{"title":"Treatment-Related AEs","categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}]},{"title":"Treatment Related Grade>=3 TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]},{"title":"irTEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) Time Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1","description":"Progression free survival (PFS) is defined as the time (in months) from first treatment day to the date of the first documentation of objective progression of disease (PD) according to RECIST version 1.1 assessed by Investigator, or death due to any cause, whichever occurs first. PD is defined as at least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"Full analysis set includes all participants who received at least one non-zero dose of any study treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time from the first dose of study drug until occurrence of PD, death due to any cause (assessed up to 737 days)","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"4.3","upperLimit":"9.0"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"DOR is defined for participants with confirmed complete response (CR) or partial response (PR), as the time from first documentation of confirmed response to the date of first documentation of progression of disease (PD) according to RECIST version 1.1 (assessed by Investigator) or death due to any cause or tumor assessment. Duration of objective response was assessed using Kaplan-Meier analysis. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.","populationDescription":"Full analysis set included all participants who receive at least one non-zero dose of any study treatment. Here \"Overall number of participants analyzed\" signifies those participants who had confirmed CR or PR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time from the first dose of study drug until occurrence of PD, death due to any cause or last tumor assessment (assessed up to 612 days)","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"4.2","upperLimit":"12.5"}]}]}]},{"type":"SECONDARY","title":"Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Avelumab","description":"Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed Avelumab concentration-time data.","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who receive at least one dose of avelumab and/or cetuximab, have no important events affecting PK, and provide at least one measurable post-dose concentration. Number of Participants Analyzed=participants evaluable for this outcome and Number analyzed=participants evaluated at specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram per milliliter (mcg/mL)","timeFrame":"Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":"26.6"}]}]},{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":"23.8"}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":"24.1"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":"26.8"}]}]},{"title":"Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"237","spread":"30.5"}]}]},{"title":"Day 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":"38.9"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":"67.6"}]}]},{"title":"Day 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"244","spread":"43.8"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":"33.3"}]}]},{"title":"Day 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"202","spread":"62.4"}]}]},{"title":"Day 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":"29.7"}]}]},{"title":"Day 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":"55.1"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":"20.8"}]}]},{"title":"Day 253","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":"28.7"}]}]},{"title":"Day 337","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":"38.6"}]}]}]},{"type":"SECONDARY","title":"Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Cetuximab","description":"Ceoi is the serum concentration observed immediately at the end of infusion. This was taken directly from the observed cetuximab concentration-time data.","populationDescription":"PK analysis set included all participants who receive at least one dose of avelumab and/or cetuximab, have no important events affecting PK, and provide at least one measurable post-dose concentration. Number analyzed=participants evaluated at specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mcg/mL","timeFrame":"Pre-dose, 2 hours after end of infusion on Day 1, 8, 22 and 29; Pre-dose, 30 minutes after the end of infusion on Day 43, 50, 64, 71; Pre-dose, 3 hours after end of infusion on Day 85, 99, 113, 127, 169, 253, and 337","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":"50.7"}]}]},{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":"86.6"}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":"54.4"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"260","spread":"25.0"}]}]},{"title":"Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":"32.7"}]}]},{"title":"Day 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"238","spread":"28.9"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":"36.1"}]}]},{"title":"Day 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"262","spread":"25.1"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":"38.4"}]}]},{"title":"Day 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"252","spread":"21.1"}]}]},{"title":"Day 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":"20.4"}]}]},{"title":"Day 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":"55.8"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":"29.2"}]}]},{"title":"Day 253","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"269","spread":"34.4"}]}]},{"title":"Day 337","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"304","spread":"37.3"}]}]}]},{"type":"SECONDARY","title":"Serum Trough Concentration Levels (Ctrough) of Avelumab","description":"Ctrough is the serum concentration observed immediately before next dosing.","populationDescription":"PK analysis set included all participants who receive at least one dose of avelumab and/or cetuximab, have no important events affecting PK, and provide at least one measurable post-dose concentration. Number of Participants Analyzed=participants evaluable for this outcome and Number analyzed=participants evaluated at specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mcg/mL","timeFrame":"Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":"82.7"}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"97.1"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":"147.8"}]}]},{"title":"Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"115.1"}]}]},{"title":"Day 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":"77.9"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"145.7"}]}]},{"title":"Day 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":"62.5"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"70.9"}]}]},{"title":"Day 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.2","spread":"75.4"}]}]},{"title":"Day 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"78.5"}]}]},{"title":"Day 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"107.6"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"67.2"}]}]},{"title":"Day 253","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":"80.1"}]}]},{"title":"Day 337","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":"55.9"}]}]}]},{"type":"SECONDARY","title":"Serum Trough Concentration Levels (Ctrough) of Cetuximab","description":"Ctrough is the serum concentration observed immediately before next dosing.","populationDescription":"PK analysis set included all participants who receive at least one dose of avelumab and/or cetuximab, have no important events affecting PK, and provide at least one measurable post-dose concentration. Number of Participants Analyzed=participants evaluable for this outcome and Number analyzed=participants evaluated at specified time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mcg/mL","timeFrame":"Pre-dose: Day 8, Day 22, Day 29, Day 43, Day 50, Day 64, Day 71, Day 85, Day 99, Day 113, Day 127, Day 169, Day 253 and Day 337","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"classes":[{"title":"Day 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"90.0"}]}]},{"title":"Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"63.7"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":"73.3"}]}]},{"title":"Day 43","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":"103.7"}]}]},{"title":"Day 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"118.1"}]}]},{"title":"Day 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"157.9"}]}]},{"title":"Day 71","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":"110.4"}]}]},{"title":"Day 85","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":"119.4"}]}]},{"title":"Day 99","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":"117.3"}]}]},{"title":"Day 113","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"59.0"}]}]},{"title":"Day 127","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":"63.6"}]}]},{"title":"Day 169","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.4","spread":"62.2"}]}]},{"title":"Day 253","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":"237.7"}]}]},{"title":"Day 337","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":"204.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from the first treatment day to the date of death due to any cause. Overall survival was assessed using Kaplan-Meier analysis.","populationDescription":"Full analysis set includes all participants who received at least one non-zero dose of any study treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Time from the first dose of study drug until occurrence of death due to any cause (assessed up to 941 days)","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"8.6","upperLimit":"14.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-Drug Antibody (ADA) of Avelumab","description":"The detection of antibodies to avelumab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of avelumab were reported.","populationDescription":"ADA analysis set included all participants who received at least 1 dose of avelumab and/or cetuximab and have at least 1 valid ADA result.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Pre-dose up to 149 days","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Positive Anti-Drug Antibody (ADA) of Cetuximab","description":"The detection of antibodies to cetuximab was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive anti-drug antibody (ADA) of cetuximab were reported.","populationDescription":"ADA analysis set included all participants who received at least 1 dose of avelumab and/or cetuximab and have at least 1 valid ADA result.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Pre-dose up to 149 days","groups":[{"id":"OG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Time from the first dose of study drug until 941 days.","eventGroups":[{"id":"EG000","title":"Avelumab and Cetuximab","description":"Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m\\^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m\\^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m\\^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.","deathsNumAffected":30,"deathsNumAtRisk":43,"seriousNumAffected":20,"seriousNumAtRisk":43,"otherNumAffected":39,"otherNumAtRisk":43}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":43}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Dry gangrene","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Femoral artery embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":43}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":43}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":43}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":43}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":43}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":43}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":43}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":43}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":43}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":43}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Transaminases increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":43}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":43}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":43}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":43}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":43}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 24.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":43}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Communication Center","organization":"Merck KGaA, Darmstadt, Germany","email":"service@emdgroup.com","phone":"+49-6151-72-5200"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-08-20","uploadDate":"2021-09-23T10:03","filename":"Prot_000.pdf","size":14335409},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-08-10","uploadDate":"2021-09-23T10:03","filename":"SAP_001.pdf","size":5677549}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Germany"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000609138","term":"avelumab"},{"id":"D000068818","term":"Cetuximab"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}